More about Jubilant Ingrevia Limited
Fundamentals for Jubilant Ingrevia Limited
Regulatory Filings for Jubilant Ingrevia Limited
The Renewable Success Story Beyond Solar
Startups Mint India’s New Billionaires
India's Biggest IPO Has a Bigger Meaning
From Watches to Wealth: Titan's New Empire
Fundamentals for Jubilant Ingrevia Limited
Business Operations:
Sector: Basic MaterialsIndustry: Specialty Chemicals
Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Revenue projections:
Jubilant Ingrevia Limited's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 1.28600 |
|---|---|
| forwardPE | 20.62992 |
| debtToEquity | 25.32800 |
| earningsGrowth | 0.16100 |
| revenueGrowth | 0.12100 |
| grossMargins | 0.38182 |
| operatingMargins | 0.09692 |
| trailingEps | 17.53000 |
| forwardEps | 30.12857 |
JUBLINGREA's current ratio of 1.286 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring JUBLINGREA is unlikely to face difficulties in meeting immediate financial obligations.
With Jubilant Ingrevia Limited's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
JUBLINGREA's low Debt-to-Equity ratio highlights its minimal reliance on debt, showing that the company is not over-leveraged. This contributes to lower financial risk and greater stability, giving JUBLINGREA a stronger position in managing its financial obligations.
Jubilant Ingrevia Limited's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as Jubilant Ingrevia Limited's increasing profits and sales signal further growth in the near future.
Jubilant Ingrevia Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Jubilant Ingrevia Limited's financial performance will improve in the current financial year.
Price projections:
The price of JUBLINGREA has often been situated close to the lower end of projections. This consistent trend may signal difficulties for the company in achieving investor expectations for future performance.
Insider Transactions:
There were 2 transactions selling Jubilant Ingrevia Limited stock, with prevailing market price of 686.4500122070312.Jubilant Ingrevia Limited had 20 buy transactions while market price was at 644.4275024414062 per share.With more buying than selling around JUBLINGREA's current price, investors could be expressing optimism. This trend may suggest that the market expects favorable outcomes for the stock, leading to an increased demand at these levels.
Recommendation changes over time:
Analysts' buy bias for Jubilant Ingrevia Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Jubilant Ingrevia Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
SEBI's New Gateway Is Rewiring Foreign Investment in India
Why Japan Backs India’s Truckers
India's $69B Eurasian Trade Power Play